Republican revolt threatens Senate drug pricing billA bipartisan bill voted through by the Senate Finance Committee last week is under threat from a group Share XRepublican revolt threatens Senate drug pricing billhttps://pharmaphorum.com/news/republican-revolt-threatens-senate-drug-pricing-bill/
Allergan pulls breast implants after link to rare cancerAllergan has followed through on an FDA request to carry out a worldwide recall of textured breast implant Share XAllergan pulls breast implants after link to rare cancerhttps://pharmaphorum.com/news/allergan-pulls-breast-implants-after-link-to-rare-cancer/
Vertex presses go on its cystic fibrosis triple filingVertex has launched the next phase of its plan for the cystic fibrosis market, filing for approval of Share XVertex presses go on its cystic fibrosis triple filinghttps://pharmaphorum.com/news/vertex-presses-go-on-its-cystic-fibrosis-triple-filing/
Celgene gets new approval for soon-to-be-shed OtezlaCelgene has picked up a third approval for its anti-inflammatory drug Otezla, although it won’t reap much commercial Share XCelgene gets new approval for soon-to-be-shed Otezlahttps://pharmaphorum.com/news/celgene-gets-new-approval-for-soon-to-be-shed-otezla/
Scotland backs Pfizer’s Ibrance for breast cancerPfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced Share XScotland backs Pfizer’s Ibrance for breast cancerhttps://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/
Federal court puts kibosh on Trump plan for drug prices in TV adsA federal judge has blown a hole in an attempt by the Trump administration to force drugmakers to Share XFederal court puts kibosh on Trump plan for drug prices in TV adshttps://pharmaphorum.com/news/federal-court-puts-kibosh-on-trump-plan-for-drug-prices-in-tv-ads/
AMAG bags FDA okay for second ‘female Viagra’ drugAMAG Pharma has won US approval for a new drug to treat decreased libido in premenopausal that will Share XAMAG bags FDA okay for second ‘female Viagra’ drughttps://pharmaphorum.com/news/amag-bags-fda-okay-for-second-female-viagra-drug/
NICE backs Alimera’s three-year uveitis implantAn implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that Share XNICE backs Alimera’s three-year uveitis implanthttps://pharmaphorum.com/news/nice-backs-alimeras-three-year-uveitis-implant/
Vaccines mistrust a “global crisis” says Wellcome reportA wide-ranging survey involving 140,000 people in 140 countries has revealed a worryingly high level of concern about Share XVaccines mistrust a “global crisis” says Wellcome reporthttps://pharmaphorum.com/news/vaccines-mistrust-a-global-crisis-says-wellcome-report/
Merck claims a brace of head and neck cancer approvalsMerck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals Share XMerck claims a brace of head and neck cancer approvalshttps://pharmaphorum.com/news/merck-claims-a-brace-of-head-and-neck-cancer-approvals/
ICER posts damning report on Sarepta’s Duchenne drug Exondys 51Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of Share XICER posts damning report on Sarepta’s Duchenne drug Exondys 51https://pharmaphorum.com/news/icer-posts-damning-report-on-sareptas-duchenne-drug-exondys-51/
Roche’s entrectinib hits the mark in paediatric cancersRoche’s entrectinib for gene fusion-positive cancers has shown promising results in a range of paediatric cancers in an Share XRoche’s entrectinib hits the mark in paediatric cancershttps://pharmaphorum.com/news/roches-entrectinib-hits-the-mark-in-paediatric-cancers/
Health secretary urged to investigate epilepsy medicine shortageHealth Secretary Matt Hancock has been urged to immediately review the epilepsy medicine supply chain, after ongoing problems Share XHealth secretary urged to investigate epilepsy medicine shortagehttps://pharmaphorum.com/news/health-secretary-urged-to-investigate-epilepsy-medicine-shortage/
Medicinal cannabis seizure prompts urgent question in ParliamentHealth secretary Matt Hancock responded to an urgent question tabled by Conservative MP Sir Mike Penning yesterday, following Share XMedicinal cannabis seizure prompts urgent question in Parliamenthttps://pharmaphorum.com/news/medicinal-cannabis-seizure-prompts-urgent-question-in-parliament/
Sanders calls on FDA to allow low-cost rivals to $375k Catalyst drugUS Senator Bernie Sanders says the FDA should allow pharmacies and generic manufacturers to make low-cost copies of Share XSanders calls on FDA to allow low-cost rivals to $375k Catalyst drughttps://pharmaphorum.com/news/sanders-calls-on-fda-to-allow-low-cost-rivals-to-375k-catalyst-drug/
Price cut unlocks NICE nod for Perjeta in post-surgery breast cancerRoche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer Share XPrice cut unlocks NICE nod for Perjeta in post-surgery breast cancerhttps://pharmaphorum.com/news/price-cut-unlocks-nice-nod-for-perjeta-in-post-surgery-breast-cancer/
Doctors and patient groups struggle with CAR-T ‘hype’Managing patients’ expectations of CAR-T therapies is proving to be a huge challenge from when selection decisions are Share XDoctors and patient groups struggle with CAR-T ‘hype’https://pharmaphorum.com/news/doctors-and-patient-groups-struggle-with-car-t-hype/
Novartis makes quality of life case for Cosentyx with new dataThere is increasing recognition that skin clearance scores may not be enough to win over patients and doctors Share XNovartis makes quality of life case for Cosentyx with new datahttps://pharmaphorum.com/news/novartis-makes-quality-of-life-case-for-cosentyx-with-new-data/
